Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Ashish M. Kamat:

BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Kamat AM et al. Nat Rev Urol. (2017)

Bladder cancer. Kamat AM et al. Lancet. (2016)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. Kamat AM et al. J Immunother Cancer. (2017)

Search results

Items: 1 to 20 of 290

1.

How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-Guérin?

Kamat AM, Gontero P, Palou J.

Eur Urol Oncol. 2019 Jul 12. pii: S2588-9311(19)30094-X. doi: 10.1016/j.euo.2019.06.013. [Epub ahead of print]

PMID:
31307960
2.

Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies.

Pignot G, Loriot Y, Kamat AM, Shariat SF, Plimack ER.

Eur Urol Oncol. 2019 Jul;2(4):355-364. doi: 10.1016/j.euo.2019.01.002. Epub 2019 Jan 31. Review.

PMID:
31277773
3.

Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.

Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM.

Eur Urol Oncol. 2019 May;2(3):286-293. doi: 10.1016/j.euo.2018.08.013. Epub 2018 Sep 10.

PMID:
31200843
4.

Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer.

Williams SB, Shan Y, Ray-Zack MD, Hudgins HK, Jazzar U, Tyler DS, Freedland SJ, Swanson TA, Baillargeon JG, Hu JC, Kaul S, Kamat AM, Gore JL, Mehta HB.

JAMA Surg. 2019 Jun 5:e191629. doi: 10.1001/jamasurg.2019.1629. [Epub ahead of print]

PMID:
31166593
5.

Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.

Lotan Y, Black PC, Caba L, Chang SS, Cookson MS, Daneshmand S, Kamat AM, McKiernan JM, Pruthi RS, Ritch CR, Steinberg GD, Svatek RS, Zwarthoff EC.

Eur Urol Oncol. 2018 Aug;1(3):223-230. doi: 10.1016/j.euo.2018.04.010. Epub 2018 May 15. Review.

PMID:
31102625
6.

Role of Checkpoint Inhibition in Localized Bladder Cancer.

Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM.

Eur Urol Oncol. 2018 Aug;1(3):190-198. doi: 10.1016/j.euo.2018.05.002. Epub 2018 May 30. Review.

PMID:
31102620
7.

Welcome to European Urology Oncology: Your New Journal, Where Multiple Disciplines Meet To Improve Care of Patients with Genitourinary Cancers.

Briganti A, Albiges L, Giannarini G, Kamat AM, Nguyen PL.

Eur Urol Oncol. 2018 May;1(1):1-2. doi: 10.1016/j.euo.2018.04.002. Epub 2018 May 15. No abstract available.

PMID:
31100222
8.

Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts.

Maulhardt HA, Hylle L, Frost MV, Tornio A, Dafoe S, Drummond L, Quinn DI, Kamat AM, diZerega GS.

Cancers (Basel). 2019 Apr 24;11(4). pii: E577. doi: 10.3390/cancers11040577.

9.

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.

Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, Malmström PU, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.

Nat Rev Urol. 2019 Jun;16(6):377-386. doi: 10.1038/s41585-019-0184-4. Review.

PMID:
31019310
10.

Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer.

Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, Black PC, Kamat AM, Goebell PJ, Seiler R, Schmitz-Drager B, Nawroth R, Baillargeon J, Klaassen Z, Kulkarni GS, Kim SP, Lee EK, Holzbeierlein JM, Hollenbeck BK, Gore JL.

Eur Urol Oncol. 2019 Mar;2(2):119-125. doi: 10.1016/j.euo.2018.07.006. Epub 2018 Aug 14.

PMID:
31017086
11.

Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study.

Flannery K, Boyd M, Black-Shinn J, Robert N, Kamat AM.

Future Oncol. 2019 Apr;15(12):1323-1334. doi: 10.2217/fon-2018-0654. Epub 2019 Apr 3.

PMID:
30942088
12.

The role of metastatic burden in cytoreductive/consolidative radical cystectomy.

Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, González GMN, Kamat AM, Pisters LL, Dinney CP, Navai N.

World J Urol. 2019 Mar 12. doi: 10.1007/s00345-019-02693-y. [Epub ahead of print]

PMID:
30864005
13.

New horizons in bladder cancer research.

Boormans JL, Zwarthoff EC, Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ.

Urol Oncol. 2019 Mar 7. pii: S1078-1439(18)30508-8. doi: 10.1016/j.urolonc.2018.12.014. [Epub ahead of print] Review.

PMID:
30852032
14.

Clinical and Genomic Considerations for Variant Histology in Bladder Cancer.

Matulay JT, Narayan VM, Kamat AM.

Curr Oncol Rep. 2019 Feb 26;21(3):23. doi: 10.1007/s11912-019-0772-8. Review.

PMID:
30806832
15.

The impact of squamous histology on survival in patients with muscle-invasive bladder cancer.

Matulay JT, Woldu SL, Lim A, Narayan VM, Li G, Kamat AM, Anderson CB.

Urol Oncol. 2019 Jun;37(6):353.e17-353.e24. doi: 10.1016/j.urolonc.2019.01.020. Epub 2019 Jan 28.

PMID:
30704959
16.

Editorial: Basic research in bladder cancer - refining the tools. 3rd IBCN seminars series1.

Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ.

Urol Oncol. 2019 Jan 22. pii: S1078-1439(19)30003-1. doi: 10.1016/j.urolonc.2019.01.003. [Epub ahead of print] Review.

PMID:
30683454
17.

Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what.

Peyton CC, Chipollini J, Azizi M, Kamat AM, Gilbert SM, Spiess PE.

World J Urol. 2018 Dec 7. doi: 10.1007/s00345-018-2591-1. [Epub ahead of print]

PMID:
30535583
18.

Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer-Reply.

Williams SB, Kamat AM, Mehta HB.

JAMA Surg. 2018 Nov 21. doi: 10.1001/jamasurg.2018.4372. [Epub ahead of print] No abstract available.

PMID:
30476959
19.

Hospital length of stay following radical cystectomy for muscle-invasive bladder cancer: Development and validation of a population-based prediction model.

Ray-Zack MD, Shan Y, Mehta HB, Yu X, Kamat AM, Williams SB.

Urol Oncol. 2018 Nov 13. pii: S1078-1439(18)30431-9. doi: 10.1016/j.urolonc.2018.10.024. [Epub ahead of print] Review.

PMID:
30446462
20.

Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.

Williams SB, Kamat AM, Chamie K, Froehner M, Wirth MP, Wiklund PN, Black PC, Steinberg GD, Boorjian SA, Daneshmand S, Goebell PJ, Pohar KS, Shariat SF, Thalmann GN.

Eur Urol Oncol. 2018 Jun;1(2):91-100. doi: 10.1016/j.euo.2018.03.005. Epub 2018 Jun 6.

Supplemental Content

Loading ...
Support Center